Non small cell lung cancer (NSCLC) is the most common form of lung cancer and remains a leading cause of cancer related mortality worldwide. Activating HER2 mutations occur in approximately 2% to 4% of advanced NSCLC cases, defining a distinct molecular subgroup that frequently affects individuals who have never smoked. Patients with HER2 mutant NSCLC typically face a poor clinical prognosis and, until recently, have had limited targeted treatment options (1). Unmet Needs in